- Home
- AGEN
AGEN
Agenus Inc.
as 11-20-2025 3:39pm EST
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 126.8M | IPO Year: | 2000 |
| Target Price: | $14.50 | AVG Volume (30 days): | 460.1K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.38 - $7.34 | Next Earning Date: | 11-10-2025 |
| Revenue: | $106,829,000 | Revenue Growth: | -33.41% |
| Revenue Growth (this year): | 60.49% | Revenue Growth (next year): | -19.74% |
Latest Agenus Inc. News
AGEN Breaking Stock News: Dive into AGEN Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC
Zacks Small Cap Research
10 days ago
LGND: Target Up On Improved Growth Outlook
Zacks
10 days ago
Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates
Associated Press Finance
10 days ago
Agenus: Q3 Earnings Snapshot
Business Wire
10 days ago
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
Zacks
14 days ago
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates
Zacks
15 days ago
Innoviva (INVA) Q3 Earnings and Revenues Beat Estimates
Business Wire
15 days ago
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report
Compare AGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AGEN Agenus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.